We are live on
!
Find out more
Marshall Wace Portfolio holdings
AUM
$100B
1-Year Est. Return
35.1%
This Fund
S&P 500
This Quarter
Est. Return
+10%
1 Year Est. Return
+35.1%
3 Year Est. Return
+111.04%
5 Year Est. Return
+146.93%
10 Year Est. Return
+631.22%
AUM
$44.5B
AUM Growth
-$1.18B
(-2.6%)
Cap. Flow
-$4.15B
Cap. Flow
% of AUM
-9.34%
Top 10 Holdings %
Top 10 Hldgs %
9.83%
Holding
3,927
New
652
Increased
690
Reduced
847
Closed
1,056
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Biogen
BIIB
|
+$309M |
| 2 |
ExxonMobil
XOM
|
+$302M |
| 3 |
Amazon
AMZN
|
+$291M |
| 4 |
Citigroup
C
|
+$253M |
| 5 |
Shopify
SHOP
|
+$238M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Humana
HUM
|
+$383M |
| 2 |
Johnson & Johnson
JNJ
|
+$312M |
| 3 |
JPMorgan Chase
JPM
|
+$285M |
| 4 |
AT&T
T
|
+$191M |
| 5 |
Dollar General
DG
|
+$187M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 15.63% |
| 2 | Financials | 15.61% |
| 3 | Technology | 14.28% |
| 4 | Consumer Discretionary | 13.21% |
| 5 | Industrials | 5.22% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
AZEK
2576
DELISTED
The AZEK Co
AZEK
| $262K | ﹤0.01% |
12,900
-160,318
| -93% | -$2.97M |
|
2577
Braze
BRZE
$3.02B
| $262K | ﹤0.01% |
9,600
| – | – |
|
|
CGC
2578
Canopy Growth
CGC
$376M
| $260K | ﹤0.01% |
+11,237
| New | +$347K |
|
2579
OraSure Technologies
OSUR
$273M
| $258K | ﹤0.01% |
53,584
-308,839
| -85% | -$1.42M |
|
|
CHEAW
2580
CALL
DELISTED
Chenghe Acquisition Co. Warrant
CHEAW
| $257K | ﹤0.01% |
24,999
| – | – |
|
|
BBBY
2581
Bed Bath & Beyond
BBBY
$479M
| $257K | ﹤0.01% |
+14,630
| New | +$315K |
|
2582
NETSCOUT
NTCT
$2.83B
| $257K | ﹤0.01% |
+7,900
| New | +$273K |
|
2583
DLH Holdings
DLHC
$78.3M
| $257K | ﹤0.01% |
21,616
-18,005
| -45% | -$232K |
|
2584
Old Dominion Freight Line
ODFL
$46.3B
| $257K | ﹤0.01% |
+1,808
| New | +$257K |
|
2585
American Superconductor
AMSC
$1.29B
| $256K | ﹤0.01% |
69,669
-14,072
| -17% | -$55.1K |
|
2586
Boyd Gaming
BYD
$6.75B
| $256K | ﹤0.01% |
4,700
-42,600
| -90% | -$2.4M |
|
2587
Stratasys
SSYS
$666M
| $256K | ﹤0.01% |
21,585
-4,700
| -18% | -$62.7K |
|
2588
Dyne Therapeutics
DYN
$4.68B
| $256K | ﹤0.01% |
22,052
-42,858
| -66% | -$496K |
|
2589
Fox Factory Holding Corp
FOXF
$794M
| $255K | ﹤0.01% |
+2,800
| New | +$260K |
|
2590
NETGEAR
NTGR
$612M
| $254K | ﹤0.01% |
+14,000
| New | +$276K |
|
2591
First Trust Nasdaq Oil & Gas ETF
FTXN
$163M
| $254K | ﹤0.01% |
9,067
-233
| -3% | -$6.72K |
|
2592
Blue Owl Capital
OWL
$6.45B
| $253K | ﹤0.01% |
+23,900
| New | +$252K |
|
|
FSRXW
2593
CALL
DELISTED
FinServ Acquisition Corp. II Warrant
FSRXW
| $253K | ﹤0.01% |
24,996
| – | – |
|
|
VLRS
2594
Controladora Vuela Compania de Aviacion
VLRS
$869M
| $251K | ﹤0.01% |
30,018
-37,996
| -56% | -$337K |
|
2595
Colgate-Palmolive
CL
$74.8B
| $250K | ﹤0.01% |
3,178
-559,898
| -99% | -$42M |
|
2596
Bio-Rad Laboratories Class A
BIO
$8.76B
| $250K | ﹤0.01% |
595
-172,005
| -100% | -$69.4M |
|
2597
Everspin Technologies
MRAM
$303M
| $250K | ﹤0.01% |
44,992
-2,679
| -6% | -$15.7K |
|
2598
West Pharmaceutical
WST
$23.7B
| $249K | ﹤0.01% |
1,056
-112,121
| -99% | -$26.6M |
|
2599
Rapid7
RPD
$628M
| $248K | ﹤0.01% |
+7,300
| New | +$261K |
|
2600
SAP
SAP
$215B
| $248K | ﹤0.01% |
2,400
-106,878
| -98% | -$10.7M |
|
Similar funds
Marshall Wace's Q4 2022 Portfolio in Review
As of Q4 2022, Marshall Wace held 3,927 positions worth $44.5B, down 2.6% from $45.6B the previous quarter. Its ten largest holdings account for 9.8% of the portfolio.
Marshall Wace withdrew a net $4.15B in Q4 2022, closing 1,056 positions and reducing 847 holdings. Its most notable exit was Humana, an estimated $383M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 16% of assets, up from 15% a quarter earlier, followed by Financials and Technology.
Against the trend, Marshall Wace opened a new position in Elevance Health worth $188M.
- Marshall Wace's largest Q4 2022 buy was Elevance Health: 366,649 shares worth $188M.
- Marshall Wace added most to Biogen in Q4 2022, an estimated $309M increase.
- Marshall Wace's biggest Q4 2022 reduction was Johnson & Johnson, cutting an estimated $312M.
- Marshall Wace fully exited Humana in Q4 2022, selling an estimated $383M.
- Marshall Wace's ten largest holdings make up 9.8% of its $44.5B portfolio in Q4 2022.
- Marshall Wace opened 652 new positions and closed 1,056 in Q4 2022.
- Marshall Wace's portfolio value fell 2.6% quarter-over-quarter to $44.5B.
Based on Marshall Wace's 13F filing for Q4 2022, filed 14 Feb 2023.